Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of pHyph, bringing this treatment earlier to patients in need.
EIC Accelerator is the most competitive program of its kind in Europe – for the November 2023 cutoff only 42 out of 1083 (~4%) applicants were selected for funding.
The final decision was taken by a highly experienced jury who verified the uniqueness and commercial potential of pHyph